Selegiline Hydrochloride is indicated for the treatment of Parkinson's disease.

Parkinson's Disease

1.25 mg administered once a day for at least 6 weeks should be the starting dose. If a desired benefit has not been reached after 6 weeks and the patient is tolerating Selegiline HCl, the dose may be increased to 2.5 mg once day. There is no evidence that doses higher than 2.5 mg per day provide any further benefit, and they should generally be avoided due to the increased risk of side effects.

• Stomatitis
• Sleeping disorders
• confusion
• hallucinations
• depression
• Abnormal movements
• dizziness
• headache
• impaired balance
• tremor
• Vertigo
• Bradycardia
• hypotension
• hypertension
• Arthralgia
• back pain
• muscle cramps
• Fatigue
• Liver dysfunction

Stomatitis	Confusion	Dizziness	Headache
Hypotension (Low Blood Pressure)	Arthralgia	Fatigue	Liver problems

• Selegiline HCl should not be used at daily doses exceeding those recommended (2.5 mg/day) because of the risks associated with non-selective inhibition of MAO. 
• Severe CNS toxicity associated with hyperpyrexia and death has been reported with the combination of tricyclic antidepressants and non-selective MAOIs  or a selective MAO-B inhibitor, swallowed selegiline. These adverse events have included behavioral and mental status changes, diaphoresis, muscular rigidity, hypertension, syncope, and death. 
• Epidemiological studies have shown that patients with Parkinson’s disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population. 
• Some patients given Selegiline HCl may experience an exacerbation of levodopa associated side effects, presumably due to the increased amounts of dopamine reacting with super sensitive, post-synaptic receptors.
• There was an increased report of mild oropharyngeal abnormality (e.g. swallowing pain, mouth pain, discrete areas of focal reddening, multiple foci of reddening, edema, and/or ulceration) in controlled clinical trials.